BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7647577)

  • 21. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
    Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
    Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
    Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
    Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
    Hawkins F; Rigopoulou D; Papapietro K; Lopez MB
    Calcif Tissue Int; 1994 Jan; 54(1):16-9. PubMed ID: 8118747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
    Franklyn JA; Betteridge J; Holder R; Sheppard MC
    Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study.
    Wang S; Wang Y; Zhu L; He L; Lv M; Zhang H; Wang H; Zhang F; Lai Y; Li Y; Shan Z; Teng W
    Endocrine; 2023 Jan; 79(1):113-124. PubMed ID: 36089636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.
    Diamond T; Nery L; Hales I
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1184-8. PubMed ID: 2026740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
    Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
    Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving L-thyroxine suppressive therapy.
    Mazokopakis EE; Starakis IK; Papadomanolaki MG; Batistakis AG; Papadakis JA
    Curr Med Res Opin; 2006 Jul; 22(7):1369-73. PubMed ID: 16834835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term thyroxine treatment and bone mineral density.
    Franklyn JA; Betteridge J; Daykin J; Holder R; Oates GD; Parle JV; Lilley J; Heath DA; Sheppard MC
    Lancet; 1992 Jul; 340(8810):9-13. PubMed ID: 1351654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
    Sijanovic S; Karner I
    Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study.
    Bauer M; Fairbanks L; Berghöfer A; Hierholzer J; Bschor T; Baethge C; Rasgon N; Sasse J; Whybrow PC
    J Affect Disord; 2004 Dec; 83(2-3):183-90. PubMed ID: 15555712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone mineral density and metabolism in children treated with L-thyroxine.
    Tümer L; Hasanoğlu A; Cinaz P; Bideci A
    J Pediatr Endocrinol Metab; 1999; 12(4):519-23. PubMed ID: 10417967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of suppressive doses of levothyroxine treatment on sex-hormone-binding globulin and bone metabolism.
    Lecomte P; Lecureuil N; Osorio-Salazar C; Lecureuil M; Valat C
    Thyroid; 1995 Feb; 5(1):19-23. PubMed ID: 7787428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thyroid hormone treatment aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women.
    Knudsen N; Faber J; Sierbaek-Nielsen A; Vadstrup S; Sørensen HA; Hegedüs L
    J Intern Med; 1998 Feb; 243(2):149-54. PubMed ID: 9566644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade.
    Fazio S; Biondi B; Carella C; Sabatini D; Cittadini A; Panza N; Lombardi G; Saccà L
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2222-6. PubMed ID: 7608283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter.
    Wesche MF; Tiel-V Buul MM; Lips P; Smits NJ; Wiersinga WM
    J Clin Endocrinol Metab; 2001 Mar; 86(3):998-1005. PubMed ID: 11238476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
    Kung AW; Yeung SS
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Bone mineral density in patients on long-term therapy with levothyroxine].
    Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
    Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women.
    Larijani B; Gharibdoost F; Pajouhi M; Sadjadi A; Aghakhani S; Eshraghian R; Akrami SM; Maalouf G
    J Clin Pharm Ther; 2004 Feb; 29(1):1-5. PubMed ID: 14748891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin.
    Ongphiphadhanakul B; Alex S; Braverman LE; Baran DT
    J Bone Miner Res; 1992 Oct; 7(10):1227-31. PubMed ID: 1456090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.